Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 18 | 2026Novo Initiates Zenagamtide CVOT in Obesity; Novo Enters Purchase Agreement for Three Obesity Programs with Kallyope; Health Canada Approves Sandoz Generic SemaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 18 | 2026Obesity Spotlight Series: Emerging Players to WatchPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 17 | 2026Novo Partners for Oral Drug Discovery; Bayer’s Kerendia Receives T1DM FDA Label Expansion; AbbVie’s Allergan Skincare + AOM Data; Roche Opens Boston CVRM Innovation CenterPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Sep 16 | 2026Pfizer Initiates Ph3 Berobenatide OSA Study; Novo Ph3 Zenagamtide Study in Japan; Novo and Anthropic Partner for Drug and AI DevelopmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Sep 15 | 2026Ascendis/Novo Terminate QM Sema Agreement; Novo Cagrisema Switch Study; Dexcom Appoints COO; Arrowhead ARO-DIMER-PA Data; Elvinix/Zealand ZP3022 Licensing Agreement; Lilly Terminates Ph1 Obesity Asset; Medtronic Expands Separation from MiniMed; Tracky Launches 16-Day CGM in IndiaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Sep 14 | 2026Novo Rebranding; Corbus Topline Ph1b CB1 Data; New Foundayo DTC TV Ads; New Alveus Ph2 Obesity Study; Beta Bionics Patch Pump FDA Clearance; Senseonics Integrates with Beta Bionics’s iLet AID; September CHMP AgendaPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Sep 11 | 2026Novo to Announce Org Changes; Novartis/Ionis Pelacarsen UpdatesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 10 | 2026Innovent Initiates Ph1 INHBE China-based Study in Obesity; BioLife Receives Patent for Dissolvable Obesity Medicine; Novo’s Semaglutide Approved for MASH in ChinaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 09 | 2026Ascletis FIH Oral Amylin Study; Moonwalk $70M Series B; New Lilly Obesity Asset; Kura Oncology Spins Out Diabetes Business; MannKind Partners for Inhaled GLP-1RA; NodThera Name Change and Topline Ph2 NLRP3i DataPurchase Blast
$599
Posted in: Allogeneic, Dual/triple agonist, GLP-1RA, Other, Topics Sep 08 | 2026Novartis’s Pelacarsen Misses Primary Endpoint; Wegovy Peds Data, Structure FIH Amylin Data; Novo Stops More CV Trials; Sernova and Seraxis to MergePurchase Blast
$599
Posted in: Insulin Delivery, Other, Topics Sep 04 | 2026Ionis Receives PRV; Modular Medical Signs Contract with US PBMPurchase Blast
$599
Posted in: Allogeneic, GLP-1RA, Other, Topics Sep 03 | 2026G&L and Menarini Bofanglutide Licensing Agreement; G&L FIH QW Oral GLP-1RA Study; Inventiva NATiV3 LPLV Milestone; Modular Medical Patch Pump Update; Eledon Tegoprubart Updates; Superluminal Series B Financing RoundPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Sep 02 | 2026Vertex New Trial for T1DM Cell Therapy; Novo New Oral Anti-Inflammatory Study; Novo Leadership Transition; Pfizer Amylin Market-Shaping CampaignPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Sep 01 | 2026Lilly Orfor Obesity/ORC Prevention Study; NewAmsterdam Alzheimer’s Study; Novartis to Advance IL-6 Inhibitor to Ph3; Wegovy Pill Germany Launch; Pfizer Berobenatide Japan Studies; MiniMed CY Q2 ’26 Earnings; Novo Initiates AMBITION 7Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Aug 31 | 2026Ascletis Doses First Patient in Ph3; Arrowhead ESC 2026 Investor Event; Cytokinetics ACACIA-HCM Primary Results; Amgen Repatha Sub-Analyses; Alnylam Vutrisiran Sub-Analysis; Lilly 52-Week Taltz + Tirzepatide DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Topics Aug 28 | 2026Innovent QW Oral Small Molecule GLP-1RA Study; Mounjaro CVRR Label Expansion; Pfizer China-Based Berobenatide Obesity StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Aug 27 | 2026Novo Discontinues Saxenda; Oral Wegovy Accepted for Review in China; Lilly Posts New China-Based Orfor Study; GSK Initiates New ALD StudyPurchase Blast
$599
Posted in: Other, Topics Aug 26 | 2026Gubra Receives Milestone Payment from AbbVie; Caliway Advances Lipolysis DrugPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other, Topics Aug 25 | 2026Abbott’s Libre Duo Approved by FDA; AZ Initiates Pivotal Amylin Studies; New Lilly Medicare Obesity Ad; Lilly Initiates First Clazakizumab Study; Google Pixel Watch Non-Invasive Insulin Resistance; Revier Seed Financing for HFpEF and ASCVD; Haisco Partners with US-Based VC for SpinoutPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Aug 24 | 2026Roche Licenses Muscle-Preservation AOM from Hanmi; Foundayo UK Launch; Lilly Initiates Second Ph3 Brenipatide MDD Study; Lexicon Receives Third LX9851 Milestone Payment; Biomea Completes COVALENT-211 EnrollmentPurchase Blast